Gilead Sciences has bolstered its position in the development of next-generation cancer cell therapies with a deal to absorb Tmunity Therapeutics into its Kite unit. Kite has agreed to acquire all the ...

Rivian’s financial picture improved in some areas in 2025, but the company’s full-year losses continued to grow as it ramps up spending ahead of its crucial R2 launch. This game, with an incredibly ...